| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
NMDAR antagonist 1 manufacturers
|
| | NMDAR antagonist 1 Basic information |
| Product Name: | NMDAR antagonist 1 | | Synonyms: | NMDAR antagonist 1;Pyrrolo[2,1-b]quinazoline-1-carboxamide, 7-bromo-1,2,3,9-tetrahydro-N-[2-(4-hydroxyphenyl)ethyl]-, (1S)-;(S)-7-Bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide;Inhibitor,NMDAR antagonist 1,Ionotropic glutamate receptors,inhibit,iGluR,NMDAR antagonist-1,NMDAR antagonist1 | | CAS: | 2220162-06-9 | | MF: | C20H20BrN3O2 | | MW: | 414.3 | | EINECS: | | | Product Categories: | | | Mol File: | 2220162-06-9.mol |  |
| | NMDAR antagonist 1 Chemical Properties |
| density | 1.54±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO : 5 mg/mL (12.07 mM);Water : < 0.1 mg/mL (insoluble) | | pka | 10.01±0.15(Predicted) | | form | Solid | | color | White to off-white |
| | NMDAR antagonist 1 Usage And Synthesis |
| Uses | NMDAR antagonist 1 is a potent and orally bioavailable NR2B-selective NMDAR antagonist[1]. | | References | [1] Zhang L, et al. Design, synthesis and bioevaluation of 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxylic acid derivatives as potent neuroprotective agents. Eur J Med Chem. 2018 May 10;151:27-38. DOI:10.1016/j.ejmech.2018.03.052 |
| | NMDAR antagonist 1 Preparation Products And Raw materials |
|